Oxonic Acid (potassium salt)

CAS No. 2207-75-2

Oxonic Acid (potassium salt) ( Potassium azaorotate;Potassium otastat;Potassium oxonate )

Catalog No. M20562 CAS No. 2207-75-2

Oxonic Acid (potassium salt) is a uricase inhibitor that prevents metabolism and excretion of uric acid and induces embryotoxicity and nephrotoxicity in rats.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG 41 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Oxonic Acid (potassium salt)
  • Note
    Research use only not for human use.
  • Brief Description
    Oxonic Acid (potassium salt) is a uricase inhibitor that prevents metabolism and excretion of uric acid and induces embryotoxicity and nephrotoxicity in rats.
  • Description
    Oxonic Acid (potassium salt) is a uricase inhibitor that prevents metabolism and excretion of uric acid and induces embryotoxicity and nephrotoxicity in rats.
  • Synonyms
    Potassium azaorotate;Potassium otastat;Potassium oxonate
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    uricase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2207-75-2
  • Formula Weight
    195.17
  • Molecular Formula
    C4H2KN3O4
  • Purity
    >98% (HPLC)
  • Solubility
    H2O:9.09 mg/mL (46.57 mM; Need ultrasonic)
  • SMILES
    [K+].[O-]C(=O)c1nc(=O)[nH]c(=O)[nH]1
  • Chemical Name
    Potassium 1456-tetrahydro-46-dioxo-135-triazine-2-carboxylate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Yoshisue K Masuda H Matsushima Eet al.Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur 5-chloro-24-dihydroxypyridine and potassium oxonate) to rats[J].Drug Metab Dispos. 2000 Oct;28(10):1162-7.
molnova catalog
related products
  • Cepazine

    Cefuroxime axetil is a second generation oral cephalosporin antibiotic. It was discovered by Glaxo now GlaxoSmithKline and introduced in 1987 as Zinnat.

  • EG1

    EG1, a novel specific inhibitor of Pax2 transcription activation, targets the DNA binding domain and inhibits embryonic kidney development.

  • Ac-IEPD-AFC

    Ac-IEPD-AFC (IEPD) is a substrate of Granzyme B.